Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Established targeted therapies, such as Janssen’s interleukin (IL)-12/23 inhibitor Stelara, AbbVie’s tumor necrosis factor-alpha (TNF-α) inhibitor Humira, and Novartis’s IL-17A inhibitor…
Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…
The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; nearly 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…
The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ARTs), such as Gilead’s Biktarvy and ViiV’s Dovato,…
The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…